Botulinum toxin A injectable - Allergan

Drug Profile

Botulinum toxin A injectable - Allergan

Alternative Names: Botox; GSK 1358820; Onabotulinum toxin A; Vistabel; Vistabex

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergan
  • Developer Allergan; GlaxoSmithKline; Johns Hopkins University; Temple University; Wake Forest University School of Medicine
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Membrane transport protein modulators; Neuromuscular blocking agents; Substance P release inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Muscle spasticity; Torticollis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Facial-wrinkles; Glabellar lines; Hyperhidrosis; Migraine; Muscle spasticity; Neurogenic bladder; Overactive bladder; Strabismus; Torticollis
  • Registered Equinus foot deformity
  • Phase III Raynaud's disease
  • Phase II Herpes labialis; Hypertrophy; Major depressive disorder; Musculoskeletal pain; Pain; Premature ejaculation
  • Phase I/II Pruritus
  • No development reported Benign prostatic hyperplasia
  • Discontinued Diabetic gastroparesis; Gilles de la Tourette's syndrome

Most Recent Events

  • 15 Aug 2017 Allergan terminates phase II trial in Premature ejaculation in USA and United Kingdom (IM)
  • 02 Aug 2017 GlaxoSmithKline initiates a phase III trial in Muscle spasticity in Japan (NCT03261167)
  • 19 Jul 2017 Allergan files an IND application with the US FDA for Overactive bladder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top